ArticleJournal of mid-life health
Primary Squamous Cell Carcinoma of Breast: A Short Report and Immunohistochemical Review.
Article in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary squamous cell carcinoma (SCC) of the breast is classified by the World Health Organization as a metaplastic carcinoma, meaning that it is made up solely of squamous cells that have undergone metaplasia and frequently show variable degrees of keratinization. Less than 0.1% of all invasive breast carcinomas are primary SCCs, making them incredibly uncommon. The exact cause and development of SCC in the breast remain uncertain. Some suggest it could represent an extreme form of squamous cell metaplasia progressing into adenocarcinoma, potentially explaining its mixed forms. Existing literature reveals only a handful of documented cases to date. This malignancy is notably aggressive, typically lacking hormone receptor expression (triple negative), resistant to standard treatments, and associated with a bad prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.